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Abstract
Development of colorectal cancer (CRC) may result from a dysfunctional interplay between
diet, gut microbes and the immune system. The ABC transport proteins ABCB1 (P-
glycoprotein, Multidrug resistance protein 1, MDR1), ABCC2 (MRP2) and ABCG2 (BCRP)
are involved in transport of various compounds across the epithelial barrier. Low mRNA
level of ABCB1 has previously been identified as an early event in colorectal carcinogenesis
(Andersen et al., PLoS One. 2013 Aug 19;8(8):e72119).
ABCC2 and ABCG2mRNA levels were assessed in intestinal tissue from 122 CRC
cases, 106 adenoma cases (12 with severe dysplasia, 94 with mild-moderate dysplasia)
and from 18 controls with normal endoscopy.
We found significantly higher level of ABCC2 in adenomas with mild to moderate dyspla-
sia and carcinoma tissue compared to the levels in unaffected tissue from the same individu-
al (P = 0.037, P = 0.037, and P<0.0001) and in carcinoma and distant unaffected tissue from
CRC cases compared to the level in the healthy individuals (P = 0.0046 and P = 0.036). Fur-
thermore, ABCG2mRNA levels were significantly lower in adenomas and carcinomas com-
pared to the level in unaffected tissue from the same individuals and compared to tissue from
healthy individuals (P<0.0001 for all). The level of ABCB2 in adjacent normal tissue was sig-
nificantly higher than in tissue from healthy individuals (P = 0.011).
In conclusion, this study found that ABCC2 and ABCG2 expression levels were altered
already in mild/moderate dysplasia in carcinogenesis suggesting that these ABC transport-
ers are involved in the early steps of carcinogenesis as previously reported for ABCB1.
These results suggest that dysfunctional transport across the epithelial barrier may contrib-
ute to colorectal carcinogenesis.
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Introduction
Colorectal cancer (CRC) constitutes a major health problem. It is the third most common can-
cer in the world and the number of cases has been estimated to rise from 1.36 million cases in
2012 to 2.4 million cases in 2035 worldwide [1]. The World Cancer Research Fund estimated
that half of the cases may be prevented by dietary and other lifestyle changes [1]. Early detec-
tion leading to early treatment will save lives [2]. Therefore, strategies for prevention, early de-
tection and treatment modalities are highly warranted.
CRC may be promoted by a dysfunctional interplay between diet, gut microbes and intesti-
nal immune system via intestinal inflammation [3]. Intestinal inflammation fosters signalling
molecules and genotoxic substances introducing genetic and epigenetic changes which may re-
sult in carcinogenesis [4]. The ABC transporters are involved in transport of various com-
pounds across the epithelial barrier [5]. Furthermore, the ABC transporters can interact with
bacterial pathogens and thereby potentially affect carcinogenesis [6].
The precise mechanisms by which ABC transporters may affect colorectal carcinogenesis
are not known, but published studies point at two main mechanisms.
The ABC transport proteins ABCB1 (P-glycoprotein, Multidrug resistance protein 1,
MDR1), ABCC2 (MRP2) and ABCG2 (BCRP) are abundant in the gut [7] and localise to the
apical plasma membrane of the enterocytes where they export various substrates from the in-
testinal cells into the intestinal lumen. Thus, by extruding carcinogenic substrates from the in-
testinal cells, they reduce the absorption of these substrates from the diet, thereby restricting
intestinal and systemic exposure. ABC transporters have been found to transport a variety of
both harmful and beneficial substrates such as flavonoids and phytoestrogens from fruits and
vegetables, short chain fatty acids derived from bacterial degradation of dietary fibres, cooking
carcinogens derived from cooking food at high temperature, dietary fatty acids giving rise to
pro- and anti-inflammatory signalling molecules, and other food constituents with potential ef-
fects on carcinogenesis [8–15].
Furthermore, mice lacking the ABCB1 gene (abcb1, mdr1a-/-) develop inflammation-
related colorectal cancer when exposed to commensal gut microbes [16,17]. Importantly, in-
flammation was preceded by changes in the tight junctions [18] leading to increased epithelium
permeability and activation of pathogen recognition system and changes in the gut microbial
composition [18–20] which together promoted inflammation. The inflammation did not de-
velop when the animals were kept in sterile conditions and could be prevented by antibiotics,
indicating that bacteria played an essential role [17]. These findings suggest that ABC proteins
may be involved in the interaction between luminal antigens and host intestinal immune re-
sponse. Dietary fat is also able to directly stimulate the pathogen recognition receptors toll like
receptors (TLR) [21], thereby activating signalling pathways resulting in interferon-γ (INF-γ)
and interleukin (IL)-1β secretion [22] which promote carcinogenesis [3,23,24]. ABC transport-
ers are involved in excretion of signalling molecules such as eicosanoids, INF-γ, tumour necro-
sis factor-α (TNF-α) and ILs, including IL-1β, thus providing a possible link between ABC
transporters, luminal antigens and carcinogenesis [25,26]. In contrast, ABC transporters are
probably not involved in the excretion of IL-2, which has a signal sequence [25–27]. The func-
tions of the ABC transporters, including ABCG2, may be related to their transport of phospho-
lipids, thereby generating the cell membrane lipid asymmetry necessary for processes such as
vesicle transport and budding, autophagy, and apoptosis [10,28].
We have previously assessed the role of ABCB1 in colorectal carcinogenesis and the results
suggest that low level of ABCB1 is an early event in colorectal carcinogenesis [29,30]. In the
present study our aim was to assess the roles of ABCC2 and ABCG2 in the normal-adenoma-
carcinoma sequence and we therefore measured ABCC2 and ABCG2mRNA levels in intestinal
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tissues from patients with colorectal adenomas and CRC. To characterize the role of these ABC
transporters in carcinogenesis we measured the mRNA levels in adenoma and carcinoma tis-
sues and morphologically normal tissue from the patients, and in intestinal tissue from healthy
control subjects.
Materials and Methods
Study cohort
The KAM (Kolorektalkreft, arv og miljø) cohort is based on the screening group of the Norwe-
gian Colorectal Cancer Prevention study in Telemark, and enriched by a series of clinical CRC
cases operated at Telemark Hospital (Skien) and Oslo University Hospital (Oslo) as described
previously [30–33]. In short, 20,780 healthy men and women, 50–64 years of age, drawn at ran-
dom from the population registry in Oslo (urban) and the county of Telemark (mixed urban
and rural) were invited to have a flexible sigmoidoscopy screening examination. The study was
performed in accordance with the Helsinki Declaration. The Regional Ethics Committee and
the Data Inspectorate approved the KAM study (S-98190, 2009/2021). The ID number for the
study is NCT00119912 at ClinicalTrials.gov. All participants gave verbal and written informed
consent. The cohort has previously been analysed [30,32,34–42].
Biological Material
The present study included intestinal tissue from adenocarcinoma (122) and adenoma (106)
cases (94 with mild/moderate dysplasia and 12 with severe dysplasia) and from healthy control
cases (18), the latter were defined by having an endoscopy with normal findings. Thus, the 18
samples from healthy controls were sampled throughout the colon. From the adenoma cases,
samples were taken from the adenoma and, in addition, from unaffected sigmoideum 30 cm
from anus. For the colorectal adenocarcinoma cases, sampling was performed from the surgical
specimens. Tissue samples were taken from the cancer and two morphologically unaffected
sites adjacent and distant to the cancer (labelled adjacent and distant unaffected tissue respec-
tively). The histology was examined independently by two histopathologists, who categorised
the degree of dysplasia as either mild/moderate or severe. Consensus was reached in all cases.
Carcinomas were classified according to Dukes’ staging. Tissues were handled immediately in
liquid nitrogen after sampling.
Real-time reverse transcriptase polymerase chain reaction and
genotyping
RNA was extracted as previously described [37]. In short, E.Z.N.A, Total RNA Kit II, RNase
Free DNase kit I was used according to the instructions by the manufactures and cDNA syn-
thesis was performed using the High-Capacity cDNA Archive Kit (Life Technologies). Messen-
ger RNA levels were normalized to 18S. Since ribosomal RNA constitutes the vast majority of
RNA in cells, this corresponds in normalizing to total RNA. We have previously shown in lym-
phocytes from human volunteers mRNA that levels could be normalized to 18S or β-actin
yielding the same result [43].
Quantitative real time RT-PCR for ABCB1 was performed on a ViiA7 sequence detection
system (Life Technologies) in Universal PCRMaster Mix (part.no. 4326614, Life Technologies)
using pre-developed assays for ABCC2 (Assay ID: Hs00166123_m1), ABCG2: (Assay ID:
Hs01053790_m1), β-actin (part.no. 4310881E) and 18S (part.no. 4310893E), (Life Technolo-
gies). In a validation experiment, a dilution series was assayed by the comparative Ct method
(15). The ABCC2 and ABCG2 assays were quantitative over a range of 16-fold and 528-fold
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dilutions, respectively. ABCC2, ABCG2, β-actin and 18S were amplified in independent wells in
triplicates. The standard deviation of triplicates was 6% or less. The standard deviations on re-
peated measurements of the same sample (the control) in separate experiments were 22% and
25%, respectively, for ABCC2 and ABCG2, indicating the day-to-day variation of the assays.
Negative controls (where the RNA was not converted into cDNA) and positive controls were
included in all runs. Samples for which the 18S values fell outside the limits of the standard
curve were excluded from the study. As control, a subset of samples were reanalysed normal-
ised to β-actin.NFKB1–94ins/del (rs28362491) genotyping data was retrieved from Andersen
et al. [30].
Statistics
All statistical analyses of mRNA levels were performed using SAS (release 9.3, SAS Institute,
Cary, NC). Linear regression (PROC GLM) was used to compare mRNA levels in tissue from
healthy participants versus tissues from affected participants with adjustment for age and gen-
der. Number of cases with available data on ABCC2 and ABCG2mRNA levels were; controls
(16), adenomas (67 with mild/moderate dysplasia, 11 with severe dysplasia, and CRC cases
(100 and 98 for ABCC2 and ABCG2, respectively).
A paired t-test (PROC TTEST) was used to compare mRNA levels from unaffected and af-
fected tissue from the same individual. Data on matching samples were available from 66 cases
with mild-moderate dysplasia and 11 cases with severe dysplasia. The number of cases for com-
parison of cancer tissue with distant unaffected tissue and adjacent unaffected tissue were for
CRC; ABCC2; 63 and 66 cases, ABCG2; 82 and 83 cases, respectively.
All values of mRNA expression levels were log-transformed to correct for left-
skewed distribution.
Kruskal Wallis and Dunns Multiple Comparison test was used to analyze the association be-
tween NFKB1–94ins/del (rs28362491) genotypes and ABCC2 and ABCG2mRNA levels using
GraphPad Prism 5.
Results
The study participants are described in Table 1. Adenoma cases and controls had similar age
whereas the adenocarcinoma cases were older. The gender distribution differed between con-
trols, adenoma and adenocarcinoma cases. Consequently, all analyses were adjusted for age
and gender. There was no correlation between the ABCC2 and ABCG2mRNA levels and
Duke’s stage of the carcinoma, age or gender. As a control, we re-determined ABCG2 and
Table 1. Study participant description.
Healthy individuals Adenoma cases Carcinoma cases P-values
Mild/moderate dysplasia Severe dysplasia
No. of subjects (N) 18 94 12 122
Male (N (%)) 6 (33) 66 (70) 6 (50) 67 (55) 0.011a
Female (N (%)) 12 (67) 28 (30) 6 (50) 55 (45)
Age Mean (SD) 56.8 (4.5) 57.0 (3.6) 55.1 (3.1) 69.5 (11.9) <0.0001b
a P-value for comparison of the distribution of gender in the different groups.
b P-value for comparison of age in the different groups.
doi:10.1371/journal.pone.0119255.t001
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ABCC2mRNA levels normalized to β-actin instead of 18S in an independent analysis for a sub-
set of the samples. When the mRNA levels normalized to β-actin was plotted against mRNA
levels normalized to 18S, a correlation coefficient, r of 0.91 was found (S1 Fig), indicating a
high degree of correlation between mRNA levels normalized to the different reference genes.
ABCC2mRNA levels in intestinal tissue
The ABCC2mRNA levels in the intestinal tissue from the healthy controls, adenoma and CRC
cases are shown in Table 2 and Fig. 1.
For adenoma cases, ABCC2mRNA levels were statistically significantly increased (p =
0.037) in mild and moderate dysplasia as compared to unaffected tissue from the same individ-
ual. ABCC2mRNA levels were not statistically different from mRNA level in the healthy con-
trols with normal endoscopic findings.
For the CRC cases, the ABCC2mRNA levels were statistically significantly increased in can-
cer tissue compared to levels in both morphologically unaffected distant tissue (p = 0.0037)
and unaffected adjacent tissue (p< 0.0001) from the same individual, and compared to levels
in tissue from healthy individual (p = 0.0046). ABCC2mRNA levels in morphologically unaf-
fected tissue from cancer patients was increased compared to levels in tissue from healthy indi-
viduals, but considerable variation in the mRNA levels was seen (Fig. 1) and only the ABCC2
mRNA level in distant normal tissue was statistically significantly different from the level in tis-
sue from healthy individuals (p = 0.036).
ABCG2mRNA levels in intestinal tissue
ABCG2mRNA levels in the intestinal tissue from the healthy individuals, adenoma and CRC
cases are shown in Table 3 and Fig. 2.
ABCG2mRNA levels were statistically significantly lower in all adenoma tissues compared
to mRNA levels in unaffected tissue from the same individuals and compared to mRNA levels
in tissue from healthy individuals (all p<0.0001).
ABCG2mRNA were statistically significantly lower in cancer tissue both compared to levels
in unaffected tissue from the same person and compared to levels in tissue from healthy con-
trols (all p<0.0001). ABCG2 mRNA levels in unaffected tissue from cancer patients were
higher than the level in tissue from healthy individuals, but considerable variation was
Table 2. ABCC2 mRNA levels x 107 in intestinal tissues normalised to 18S RNA level.
unaffected tissue adenomas/carcinomas
Variable Mean ± S.D. Pa Mean ± S.D. Pa Pb
Healthy individuals 5.35 ± 3.24
Mild moderate dysplasia cases 4.62 ± 4.79 0.081 6.68 ± 6.77 0.87 0.037
Severe dysplasia cases 6.66 ± 8.47 0.88 10.18 ± 11.52 0.27 0.24
Cancer patients 28.06 ± 68.84 (distant) 0.036 87.50 ± 270.21 0.0046 0.0037
11.44 ± 25.58 (adjacent) 0.69 <0.0001
a P-values for comparison of the expression levels to the level in controls adjusted for age and gender.
b P value for the comparison of the expression levels in the morphologically affected and unaffected tissues from the same individual using Paired
Student’s t-test. Matching samples were available from 66 cases with mild-moderate dysplasia, 11 cases with severe dysplasia, and 63 and 66 CRC
cases (distant unaffected tissue and adjacent unaffected tissue, respectively).
doi:10.1371/journal.pone.0119255.t002
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observed (Fig. 2), and the difference was only statistically significant for adjacent unaffected tis-
sue (p = 0.011).
Genotype and expression level association
No associations between NFKB1–94ins/del (rs28362491) genotypes and ABCC2 and ABCG2
mRNA levels were found (S2 Fig).
Fig 1. ABCC2mRNA levels in morphologically normal and affected tissues normalised to 18S RNA
levels. P-values for comparison of the expression levels to the level in healthy controls adjusted for age and
gender are indicated. M/M, mild-to moderate dysplasia; S, severe dysplasia; Normal tissue I, morphologically
normal distant tissue; Normal tissue II, morphologically normal adjacent tissue. Horizontal bars indicate
mean. mRNA expression levels were log-transformed.
doi:10.1371/journal.pone.0119255.g001
ABCC2 and ABCG2 Expression in Colorectal Carcinogenesis
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Discussion
In the present study we found significantly higher mRNA level of ABCC2 in adenomas with
mild to moderate dysplasia and carcinoma tissue compared to the level in unaffected tissue
from the same individuals. The same was found in carcinoma and distant unaffected tissue
from CRC cases compared to the level in tissue from healthy individuals. Furthermore, we
found significantly lower level of ABCG2 in adenomas and carcinomas compared to the level
in unaffected tissue from the same individuals and as compared to tissue from healthy individ-
uals. The mRNA level of ABCG2 in adjacent normal tissue was significantly higher than in
healthy individuals.
Our findings are in agreement with previous findings in a study of ABCC2 and ABCG2
mRNA levels in normal and affected colonic tissue from 51 CRC patients [44], where ABCC2
mRNA level was higher in tumour tissue compared to unaffected tissue from the same individ-
ual, and the ABCG2mRNA levels were found to be lower [44]. Our study is also in agreement
with a study of ABCG2 and ABCC2 protein and ABCG2mRNA levels in 29 adenomas from 21
patients [45]. The authors found low levels of ABCG2 protein and ABCG2mRNA in the ade-
noma tissue using adjacent tissue as control [45]. The latter study found low ABCC2 protein
levels in control tissue and no detectable changes in the levels of the adenomas [45]. Moreover,
in an animal model, down-regulation of ABCG2 protein expression was found in adenoma tis-
sue compared to adjacent normal tissue [45]. Concurrently, high level of the ABCG2 substrate,
the he food carcinogen ation of ABCC2 affe tissue om 21 patients which found that the level of
pared to the level infood carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-β] pyridine
(PhIP) and a higher although not statistically significantly increased level of PhIP-DNA ad-
ducts were found in the intestinal adenomas as compared to adjacent tissue of these mice [45].
Our study replicates and further corroborates these previous findings by including healthy
individuals, and, furthermore, assessed the levels of ABCC2 and ABCG2 in the normal-mild
dysplasia-severe dysplasia-carcinoma sequence. The finding of lowered ABCG2 level in adeno-
mas with mild/moderate dysplasia suggests that low ABCG2 activity may hamper export of
food carcinogens in adenomas with mild/moderate dysplasia. Thereby, food carcinogens, in-
cluding PhIP, could accumulate in adenomas and thus promote carcinogenesis. However, we
detected interaction between intake of meat and genetic variants in ABCB1 but not with
ABCG2 [29]. We have previously reported low mRNA levels of ABCB1 in adenomas and
Table 3. ABCG2 mRNA levels x 107 in intestinal tissues normalised to 18S RNA levels
unaffected tissue adenomas/carcinomas
Variable Mean ± S.D. Pa Mean ± S.D. Pa Pb
Healthy individuals 718.06 ± 761.24
Mild moderate dysplasia 732.85 ± 2305.28 0.55 56.02 ± 118.42 <0.0001 <0.0001
Severe dysplasia 448.02 ± 195.34 0.84 76.31 ± 102.63 <0.0001 <0.0001
Cancer patients 6679 ± 58353 (distant) 0.080 98.41 ± 476.36 <0.0001 <0.0001
1302 ± 10090 (adjacent) 0.011 <0.0001
a P-values for comparison of the expression levels in tissue from healthy individuals adjusted for age and gender.
b P value for the comparison of the expression levels in morphologically unaffected and affected tissue from the same individual using Paired Student’s t-
test. Matching samples were available from 66 cases with mild-moderate dysplasia, 11 cases with severe dysplasia, and 80 and 83 CRC cases (distant
unaffected tissue, and adjacent unaffected tissue, respectively.
doi:10.1371/journal.pone.0119255.t003
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carcinomas and this may suggest similarities in the regulation of gene expression of these two
ABC transporters in colorectal carcinogenesis [30].
In the present study, high levels of ABCC2 gene expression were observed in adenomas with
mild/moderate dysplasia similarly suggesting that ABCC2 is involved in the early development
Fig 2. ABCG2mRNA levels in morphologically normal and affected tissues normalised to 18S RNA
levels. P-values for comparison of the expression levels to the level in healthy controls adjusted for age and
gender are indicated. M/M, mild-to moderate dysplasia; S, severe dysplasia; Normal tissue I, morphologically
normal distant tissue; Normal tissue II, morphologically normal adjacent tissue. Horizontal bars indicate
mean. mRNA expression levels were log-transformed.
doi:10.1371/journal.pone.0119255.g002
ABCC2 and ABCG2 Expression in Colorectal Carcinogenesis
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of colorectal carcinogenesis. Dietary omega-3 and omega-6 fatty acids are precursors of the ar-
achidonic acid metabolites eicosanoids, which are potent regulators of inflammation [21].
ABCC2 transports LTB4 and probably other eicosanoids [26] which are potent stimulators of
inflammatory signalling pathways leading to inflammation and cancer. Thus, high ABCC2 ac-
tivity due to high level of ABCC2mRNA could be involved in the translocation of eicosanoids
thereby promoting inflammation and carcinogenesis [28].
Regulation of ABC transporter activity may differ in normal and dysplastic/cancer intestinal
tissue. Thus, the intestinal ABCB1mRNA levels were found to be associated with polymor-
phisms in ABCB1 and NFKB1 (encoding the p50 subunit of the transcription factor nuclear
factor κB (NFκB)) in morphologically normal tissue from adenoma case, whereas no associa-
tion was found in either dysplastic tissue from adenoma cases or in morphologically normal or
cancer tissue from CRC cases [30]. Also, various transcription factors involved in xenobiotic
sensing, including pregnane X receptor (PXR), seem to be involved in the regulation of ABCB1,
ABCC2 and ABCG2mRNA levels in the normal intestine [7,46,47]. Inflammation is an indis-
pensable part of colorectal carcinogenesis [4] and inflammation has been found to down-regu-
late the expression of intestinal ABC transporters in animal studies [47–49]. In line with this,
ABCB1 and ABCG2mRNA levels were decreased in inflammatory intestinal tissue from pa-
tients with active intestinal inflammation [50]. Also, pro-inflammatory cytokines produced in
the course of inflammation [4] modulates the expression of the ABC transporters [51]. The
present study found no association between the previously reported NFKB1–94ins/del
(rs28362491) polymorphism and ABCC2 and ABCG2mRNA levels.
Multidrug resistance caused by high activity of ABC transporters is a frequent problem in
the treatment of CRC [52]. The results of the present study suggest that high ABCC2 activity in
cancer tissue even before drug treatment could contribute to inherent multidrug resistance, i.e.
that the patient does not respond to initial chemotherapy. Other mechanisms such as selection
of cancer cells overexpressing ABC transporters and induction of ABC transporters contribute
to the phenotypic development of acquired drug resistance, i.e. where initial treatment is effec-
tive but the patient subsequently develops drug resistance [52].
Interestingly, genetic variation in these two ABC transporters was not associated with risk
of inflammatory bowel disease or CRC in genetic epidemiological studies although suggestive
associations between CRC and ABCG2 rs2622621 and rs1481012 were found [29,53–55]. Also,
abcc2 and abcg2 knockout mice seemed to be healthy [56]. In humans, no overt disease has
been related to mutations in these transporters [57]. Dubin-Johnson syndrome is caused by
several different mutations in ABCC2, and is associated with a failure to excrete conjugated bil-
irubin glucuronides in the bile, resulting in elevated levels of conjugated bilirubin in the blood
[57].
Taken together, the results from the present study suggest that both ABCC2 and ABCG2
are differentially expressed in early carcinogenesis similar to ABCB1. Our results are in accor-
dance with the hypothesis that changes in the ABC transporter activity is not sufficient to initi-
ate cancer development but may increase susceptibility for dietary factors which are substrates
of the ABC transporters. Thus, modified transport across the epithelial barrier may represent
one of the early events in the adenoma-carcinoma sequence. However, the present study does
not add to the knowledge on the underlying biological mechanisms.
In conclusion, this study found that ABCC2 and ABCG2 gene expression levels were altered
in mild/moderate dysplasia in the normal-adenoma-carcinoma sequence suggesting that these
ABC transporters are involved in early carcinogenesis similar to ABCB1.
ABCC2 and ABCG2 Expression in Colorectal Carcinogenesis
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Supporting Information
S1 Fig. ABCC2 and ABCG2mRNA levels (x107) normalized to either 18S or β-actin. The
plot is shown in double log-scale since the variation in mRNA levels spans three orders
of magnitude.
(TIF)
S2 Fig. Association between NFKB1–94ins/del polymorphism and ABCC2 and ABCG2
mRNA levels in morphologically normal and affected intestinal tissue from individuals
with adenomas (left panel) and carcinomas (right panel). The number of individuals with
each genotype is indicated in brackets above the column. At the the bottom, one outlier (ex-
tremely high mRNA values) in each panel has been removed for clarity. Normal tissue I, mor-
phologically normal distant tissue; Normal tissue II, morphologically normal adjacent tissue.
Horizontal bars indicate mean with standard error. Kruskal-Wallis test was used to compare
mean mRNA expression levels followed by Dunn’s post-test.
(TIF)
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